TUT1: A Potential Drug Target and Biomarker (G55149)

Target Name: MTPAP

NCBI ID: G55149

MTPAP

TUT1: A Potential Drug Target and Biomarker

Terminal uridylyltransferase 1 (TUT1) is a gene that encodes a protein known as TUT1. TUT1 is a member of theURYLTRANSPORTER family, which is responsible for transporting various molecules including purines, such as uracils, from the cytoplasm to the endoplasmic reticulum.

TUT1 is primarily expressed in the liver and other organs, where it plays a crucial role in the regulation of uracil excretion and metabolism. It is expressed in high levels in the liver, and its expression is highly dependent on the level of uracil present in the cytoplasm.

TUT1 has been identified as a potential drug target due to its involvement in the regulation of uracil metabolism and its ability to modulate the levels of uracils in the liver. It is also expressed in high levels in various tissues and organs, including the brain, heart, and kidneys, which suggests that it may also be a potential biomarker for various diseases.

One of the key functions of TUT1 is its role in the regulation of uracil excretion. Uric acid, a byproduct of the metabolism of purines, is excreted from the body by the liver. TUT1 is involved in the transport of uracils from the cytoplasm to the endoplasmic reticulum, where they are then excreted from the body via the urine.

In addition to its role in uracil metabolism, TUT1 has also been shown to play a role in the regulation of various signaling pathways that are involved in cellular processes such as cell growth, apoptosis, and inflammation.

For example, TUT1 has been shown to be involved in the regulation of the production of reactive oxygen species (ROS), which are highly reactive molecules that can cause damage to cellular components and contribute to the development of various diseases.

TUT1 has also been shown to be involved in the regulation of the production of pro-inflammatory cytokines, such as interleukin-1尾 (IL-1尾), which are involved in the regulation of immune responses and the development of various inflammatory diseases.

In addition to its potential role as a drug target and biomarker, TUT1 is also of interest as a potential therapeutic approach for the treatment of various diseases. For example, TUT1 has been shown to be involved in the regulation of uracil metabolism in diseases such as urinary tract infection (UTI) and urinary retention, and it is possible that targeting TUT1 may be a promising approach for the treatment of these diseases.

In conclusion, TUT1 is a gene that encodes a protein that plays a crucial role in the regulation of uracil metabolism and the production of various signaling pathways. Its potential as a drug target and biomarker make it an attractive target for further research and development. Further studies are needed to fully understand the role of TUT1 in cellular processes and its potential as a therapeutic approach for the treatment of various diseases.

Protein Name: Mitochondrial Poly(A) Polymerase

Functions: Polymerase that creates the 3' poly(A) tail of mitochondrial transcripts. Can use all four nucleotides, but has higher activity with ATP and UTP (in vitro). Plays a role in replication-dependent histone mRNA degradation. May be involved in the terminal uridylation of mature histone mRNAs before their degradation is initiated. Might be responsible for the creation of some UAA stop codons which are not encoded in mtDNA

The "MTPAP Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MTPAP comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets